View Item 

Show simple item record

Women and ARVâ based prevention: opportunities and challenges
dc.contributor.authorGeary, Cynthia W
dc.contributor.authorBukusi, Elizabeth A
dc.contributor.authorStraten, Ariane
dc.contributor.authorStadler, Jonathan
dc.contributor.authorLuecke, Ellen
dc.contributor.authorLaborde, Nicole
dc.contributor.authorHartmann, Miriam
dc.contributor.authorMontgomery, Elizabeth T
dc.contributor.authorGrant, RM
dc.contributor.authorMcKenna, Kevin
dc.contributor.authorHeadley, Jennifer
dc.contributor.authorAhmed, Khatija
dc.contributor.authorOdhiambo, Jacob
dc.contributor.authorSkhosana, Joseph
dc.contributor.authorWang, Meng
dc.contributor.authorAgot, Kawango
dc.contributor.authorRosenstock, I
dc.contributor.authorSista, Nirupama
dc.contributor.authorAbdool‐karim, Quarraisha
dc.contributor.authorLanham, Michele
dc.contributor.authorWilcher, Rose
dc.contributor.authorPool, Robert
dc.contributor.authorSchuler, Sidney
dc.contributor.authorLenzi, Rachel
dc.contributor.authorFriedland, Barbara
dc.contributor.authorMacQueen, Kathleen M
dc.contributor.authorTolley, Elizabeth E
dc.contributor.authorOwen, Derek H
dc.contributor.authorAmico, K Rivet
dc.contributor.authorMorrow, Kathleen M
dc.contributor.authorMoench, Thomas
dc.contributor.authorFriend, David R
dc.contributor.authorKaaya, Sylvia
dc.contributor.authorKaale, Anna
dc.contributor.authorMinja, Anna
dc.contributor.authorBangapi, Doreen
dc.contributor.authorKalungura, Happy
dc.contributor.authorBaumgartner, Joy Noel
dc.contributor.authorSidibe, Sekou
dc.contributor.authorPack, Allison P
dc.contributor.authorRyan, Elizabeth
dc.contributor.authorBockh, Emily
dc.contributor.authorGithuka, George
dc.contributor.authorMack, Natasha
dc.contributor.authorEvens, Emily M
dc.contributor.authorBrelsford, Kate
dc.contributor.authorMackenzie, Caroline
dc.contributor.authorMilford, Cecilia
dc.contributor.authorSmit, Jennifer A
dc.contributor.authorKimani, Joshua
dc.contributor.authorWoodsong, Cynthia
dc.contributor.authorMutsambi, John Michael
dc.contributor.authorNtshele, Smangalisa
dc.contributor.authorModikoe, Peggy
dc.contributor.authorLin, Amy H
dc.contributor.authorBreger, Tiffany L
dc.contributor.authorBarnhart, Matthew
dc.contributor.authorKim, Ann
dc.contributor.authorVangsgaard, Charlotte
dc.contributor.authorHarris, Emily
dc.contributor.authorLusti‐narasimhan, Manjula
dc.contributor.authorKhosla, Rajat
dc.contributor.authorBaggaley, Rachel
dc.contributor.authorTemmerman, Marleen
dc.contributor.authorMcGrory, Elizabeth
dc.contributor.authorFarley, Tim
dc.date.accessioned2017-10-05T18:19:14Z
dc.date.available2017-10-05T18:19:14Z
dc.date.issued2014-09
dc.identifier.citationGeary, Cynthia W; Bukusi, Elizabeth A; Geary, Cynthia W; Bukusi, Elizabeth A; Straten, Ariane; Stadler, Jonathan; Luecke, Ellen; Laborde, Nicole; Hartmann, Miriam; Montgomery, Elizabeth T; Grant, RM; McKenna, Kevin; Headley, Jennifer; Ahmed, Khatija; Odhiambo, Jacob; Skhosana, Joseph; Wang, Meng; Agot, Kawango; Rosenstock, I; Sista, Nirupama; Abdool‐karim, Quarraisha ; Lanham, Michele; Wilcher, Rose; Montgomery, Elizabeth T; Pool, Robert; Schuler, Sidney; Lenzi, Rachel; Friedland, Barbara; MacQueen, Kathleen M; Tolley, Elizabeth E; Owen, Derek H; Amico, K Rivet; Morrow, Kathleen M; Moench, Thomas; Friend, David R; Friedland, Barbara; Tolley, Elizabeth E; Kaaya, Sylvia; Kaale, Anna; Minja, Anna; Bangapi, Doreen; Kalungura, Happy; Headley, Jennifer; Baumgartner, Joy Noel; Sidibe, Sekou; Pack, Allison P; Tolley, Elizabeth E; Ryan, Elizabeth; Mackenzie, Caroline; Bockh, Emily; Githuka, George; Mack, Natasha; Evens, Emily M; Tolley, Elizabeth E; Brelsford, Kate; Mackenzie, Caroline; Milford, Cecilia; Smit, Jennifer A; Kimani, Joshua; Woodsong, Cynthia; Mutsambi, John Michael; Ntshele, Smangalisa; Modikoe, Peggy; Lin, Amy H; Breger, Tiffany L; Barnhart, Matthew; Kim, Ann; Vangsgaard, Charlotte; Harris, Emily; Lusti‐narasimhan, Manjula ; Khosla, Rajat; Baggaley, Rachel; Temmerman, Marleen; McGrory, Elizabeth; Farley, Tim (2014). "Women and ARVâ based prevention: opportunities and challenges." Journal of the International AIDS Society 17: n/a-n/a.
dc.identifier.issn1758-2652
dc.identifier.issn1758-2652
dc.identifier.urihttps://hdl.handle.net/2027.42/138349
dc.publisherWiley Periodicals, Inc.
dc.publisherJohns Hopkins University School of Public Health, Population Information Program
dc.subject.otheradherence
dc.subject.otherintroduction planning
dc.subject.otherhuman rights
dc.subject.othersexual and reproductive health
dc.subject.otherHIV
dc.subject.otherprevention
dc.subject.otherpreâ exposure prophylaxis
dc.subject.othermicrobicide
dc.subject.otherHIV prevention
dc.subject.otherwomen
dc.subject.othergender
dc.subject.otherHIV prevention
dc.subject.otherARVs
dc.subject.othermicrobicides
dc.subject.otherPrEP
dc.subject.otherrisk compensation
dc.subject.otherHIV prevention
dc.subject.otherantiretroviral
dc.subject.otherpreâ exposure prophylaxis
dc.subject.othermicrobicides
dc.subject.otheradherence
dc.subject.otherSouth Africa
dc.subject.otherqualitative methods
dc.subject.otherHIV stigma
dc.subject.otherrisk perceptions
dc.subject.otherHIV worry
dc.subject.otherFEMâ PrEP
dc.subject.otherseroconversion
dc.subject.otherwomen
dc.subject.otherAfrica
dc.subject.otherHIV
dc.subject.otherAIDS
dc.subject.otherantiretroviral agents
dc.subject.otherwomen
dc.subject.otherHIV prevention
dc.subject.otherHIV treatment
dc.subject.otherPrEP
dc.subject.otherMicrobicides
dc.subject.otherHIV
dc.subject.otherqualitative research
dc.subject.otherpartner communication
dc.subject.othergender relations
dc.subject.othervaginal ring
dc.subject.otheracceptability
dc.subject.otheradherence
dc.subject.otherclinical trial research
dc.subject.otherHIV prevention
dc.subject.othermeasurement
dc.subject.otheradolescents
dc.subject.otherclinical trials research
dc.subject.othersexual and reproductive health
dc.subject.otherHIV prevention
dc.subject.otherTanzania
dc.subject.othermicrobicide
dc.subject.othercommunication
dc.subject.otherwomen
dc.subject.othermessages
dc.subject.otherKenya
dc.subject.otherpreâ exposure prophylaxis
dc.subject.othersubâ Saharan Africa
dc.subject.otherwomen
dc.subject.otherARVâ based HIV prevention methods
dc.subject.otherHIV prevention
dc.subject.othermicrobicide trials
dc.subject.othercommunity collaboration
dc.subject.otherparticipant information materials
dc.subject.otherHIV
dc.subject.otherprevention
dc.subject.othermicrobicides
dc.subject.otherendâ user
dc.subject.otheruser research
dc.subject.otherwomen
dc.titleWomen and ARVâ based prevention: opportunities and challenges
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA
dc.contributor.affiliationotherFHI 360, Durham, NC, USA
dc.contributor.affiliationotherDepartment of Medicine, Center for AIDS Prevention Studies, University of California San Francisco San Francisco, CA, USA
dc.contributor.affiliationotherWomen’s Global Health Imperative, RTI International San Francisco, CA, USA
dc.contributor.affiliationotherDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, USA
dc.contributor.affiliationotherDepartment of Obstetrics and Gynecology, Nairobi University, Nairobi, Kenya
dc.contributor.affiliationotherDepartment of Obstetrics and Gynecology Aga Khan University, Nairobi, Kenya
dc.contributor.affiliationotherDepartments of Obstetrics and Gynecology, and Global health, University of Washington, Seattle,WA, USA
dc.contributor.affiliationotherCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
dc.contributor.affiliationotherSigma 3 Services SÃ RL, Nyon, Switzerland
dc.contributor.affiliationotherConsultant, New York, NY, USA
dc.contributor.affiliationotherDepartment of HIV/AIDS, World Health Organization, Geneva, Switzerland
dc.contributor.affiliationotherDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
dc.contributor.affiliationotherReD Associates New York, NY, USA
dc.contributor.affiliationotherIDEO, Boston, MA, USA
dc.contributor.affiliationotherUnited States Agency for International Development (USAID), Office of HIV/AIDS Washington, DC, USA
dc.contributor.affiliationotherDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health Chapel Hill, NC, USA
dc.contributor.affiliationotherUnited States Agency for International Development (USAID), Center for Accelerating Innovation and Impact Washington, DC, USA
dc.contributor.affiliationotherTB/HIV Care Association, Cape Town, South Africa
dc.contributor.affiliationotherInternational Partnership for Microbicides, Paarl, South Africa
dc.contributor.affiliationotherCommunity Engagement Consultant, Cape Town, South Africa
dc.contributor.affiliationotherInternational Partnership for Microbicides, Silver Spring, MD, USA
dc.contributor.affiliationotherKenya AIDS Control Project, Nairobi, Kenya
dc.contributor.affiliationotherMatCH (Maternal, Adolescent and Child Health), Durban, South Africa
dc.contributor.affiliationotherApplied Research Unit, FHI 360, Nairobi, Kenya
dc.contributor.affiliationotherDuke Clinical Research Institute, Duke University, Durham, NC, USA
dc.contributor.affiliationotherHealth Services Research, FHI 360, Durham, NC, USA
dc.contributor.affiliationotherSocial and Behavioral Health Sciences, FHI 360, Durham, NC, USA
dc.contributor.affiliationotherNational AIDS and STI Control Programme, Nairobi, Kenya
dc.contributor.affiliationotherResearch, FHI 360, Nairobi, Kenya
dc.contributor.affiliationotherSocial Marketing and Communication, FHI 360, Washington, DC, USA
dc.contributor.affiliationotherSocial & Behavioural Health Sciences, FHI360, Durham, NC, USA
dc.contributor.affiliationotherMuhimbili University of Health and Allied Services, Dar es Salaam, Tanzania
dc.contributor.affiliationotherSocial and Behavioral Health Sciences, FHI 360 Durham, NC, USA
dc.contributor.affiliationotherPopulation Council, New York, NY, USA
dc.contributor.affiliationotherProduct Development, CONRAD, Arlington, VA, USA
dc.contributor.affiliationotherThe Johns Hopkins University, Baltimore, MD, USA
dc.contributor.affiliationotherReprotect Inc, Baltimore, MD, USA
dc.contributor.affiliationotherDepartment of Psychiatry & Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA
dc.contributor.affiliationotherCenters for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, RI, USA
dc.contributor.affiliationotherContraceptive Technology Institute, FHI 360, Durham, NC, USA
dc.contributor.affiliationotherSocial and Behavioral Health Sciences, FHI 360, Durham, NC, USA
dc.contributor.affiliationotherHIV and AIDS Program, Population Council New York, NY, USA
dc.contributor.affiliationotherCentre for Social Science and Global Health, University of Amsterdam, Amsterdam, The Netherlands
dc.contributor.affiliationotherWomen’s Global Health Imperative, RTI International, San Francisco Project Office San Francisco, CA, USA
dc.contributor.affiliationotherResearch Utilization, FHI 360 Durham, NC, USA
dc.contributor.affiliationotherSocial and Behavioral Health Sciences, FHI 360 Durham, NC, USA
dc.contributor.affiliationotherCAPRISA, Durban, South Africa
dc.contributor.affiliationotherFHI 360, Durham, North Carolina, USA
dc.contributor.affiliationotherQuantitative Sciences, Durham, NC FHI 360, USA
dc.contributor.affiliationotherImpact Research and Development Organization, Kisumu, Kenya
dc.contributor.affiliationotherSetshaba Research Centre, Soshanguve, South Africa
dc.contributor.affiliationotherSocial and Behavioral Health Sciences, FHI 360, Durham, NC, USA
dc.contributor.affiliationotherWits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138349/1/jia29419.pdf
dc.identifier.doi10.7448/IAS.17.3.19419
dc.identifier.sourceJournal of the International AIDS Society
dc.identifier.citedreferenceJaspan HB, Flisher AJ, Myer L, Mathews C, Middelkoop K, Mark D, et al. Sexual health, HIV risk, and retention in an adolescent HIVâ prevention trial preparatory cohort. J Adolesc Health. 2011; 49: 42 â 6.
dc.identifier.citedreferenceMngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014; 18 ( 5 ): 849 â 54.
dc.identifier.citedreferenceSuccop SM, MacQueen KM, van Loggerenberg F, Majola N, Abdool Karim Q, Abdool Karim SS. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care. 2014.
dc.identifier.citedreferenceMontgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women’s acceptability and adherence to femaleâ initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2011; 15 ( 5 ): 959 â 69.
dc.identifier.citedreferenceWare NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral preexposure prophylaxis for HIVâ serodiscordant couples. J Acquir Immune Defic Syndr. 2012; 59 ( 5 ): 463 â 8.
dc.identifier.citedreferenceMontgomery ET, van der Straten A, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. Vaginal ring adherence in subâ Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012; 16 ( 7 ): 1787 â 98.
dc.identifier.citedreferenceNel A, Kamupira M, Woodsong C, van der Straten A, Montgomery E, van Niekerk N, et al., editors. Safety, acceptability and pharmacokinetic assessment (adherence) of monthly dapivirine vaginal rings (Ringâ 004) for HIV prevention. CROI; 2012 Mar 3â 8; Seattle, Washington, DC: International Partnership for Microbicides; 2012.
dc.identifier.citedreferencevan der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep. 2013; 10 ( 1 ): 89 â 102.
dc.identifier.citedreferenceTolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010; 14 ( 5 ): 1124 â 36.
dc.identifier.citedreferenceKiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012; 14 ( 1 ): 62 â 77.
dc.identifier.citedreferenceFenton KA, Johnson AM, McManus S, Erens B. Measuring sexual behaviour: methodological challenges in survey research. Sex Transm Infect. 2001; 77 ( 2 ): 84 â 92.
dc.identifier.citedreferenceCatania JA, Binson D, van Der Straten A, Stone V. Methodological research on sexual behavior in the AIDS era. Ann Rev Sex Res. 1995; 6 ( 1 ): 77 â 125.
dc.identifier.citedreferenceMuchomba FM, Gearing RE, Simoni JM, Elâ Bassel N. State of science of adherence in preâ exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012; 61 ( 4 ): 490 â 8.
dc.identifier.citedreferencePool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One. 2010; 5 ( 7 ): 11600.
dc.identifier.citedreferenceAmico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013; 17 ( 6 ): 2143 â 55.
dc.identifier.citedreferenceAmico KR, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in selfâ report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012; 16 ( 5 ): 1243 â 59.
dc.identifier.citedreferenceMansoor LE, Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, et al. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav. 2014; 18: 841 â 8.
dc.identifier.citedreferenceSafren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: lifeâ steps and medication monitoring. Behav Res Ther. 2001; 39 ( 10 ): 1151 â 62.
dc.identifier.citedreferencePsaros C, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD, et al. An intervention to support HIV preâ exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda. J Acquir Immune Defic Syndr. 2014; 66: 522 â 9.
dc.identifier.citedreferenceHolstad MM, Foster V, Diiorio C, McCarty F, Teplinskiy I. An examination of the psychometric properties of the Antiretroviral General Adherence Scale (AGAS) in two samples of HIVâ infected individuals. J Assoc Nurses AIDS Care. 2010; 21 ( 2 ): 162 â 72.
dc.identifier.citedreferenceRubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and metaâ analysis. Br J Gen Pract. 2005; 55 ( 513 ): 305 â 12.
dc.identifier.citedreferenceJoint United Nations Programme on HIV/AIDS (UNAIDS), AVAC. Good participatory practice guidelines for biomedical HIV prevention trials. 2nd ed. Geneva, Switzerland: UNAIDS; 2011.
dc.identifier.citedreferenceParticipants in the Conference on Ethical Aspects of Research in Developing Countries. Ethics. Fair benefits for research in developing countries. Science. 2002; 298 ( 5601 ): 2133 â 4.
dc.identifier.citedreferenceRennie S, Sugarman J. Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach. J Med Ethics. 2010; 36 ( 12 ): 810 â 5.
dc.identifier.citedreferenceDewing S, Mathews C, Schaay N, Cloete A, Louw J, Simbayi L. Behaviour change counselling for ARV adherence support within primary health care facilities in the Western Cape, South Africa. AIDS Behav. 2012; 16 ( 5 ): 1286 â 94.
dc.identifier.citedreferenceMorisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfâ reported measure of medication adherence. Med Care. 1986; 24 ( 1 ): 67 â 74.
dc.identifier.citedreferenceJohnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA. The role of selfâ efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Selfâ Efficacy Scale (HIVâ ASES). J Behav Med. 2007; 30 ( 5 ): 359 â 70.
dc.identifier.citedreferenceDeVellis RF. Scale development theory and applications. 2nd ed. Thousand Oaks, CA: Sage; 2003.
dc.identifier.citedreferenceMahoney CA, Thombs DL, Howe CZ. The art and science of scale development in health education research. Health Educ Res. 1995; 10 ( 1 ): 1 â 10.
dc.identifier.citedreferenceGamst G, Meyers L, Guarino AJ, Burke HM. Scale development and validation. In: Guest G, Namey E, editors. Public health research methods [Internet]. Thousand Oaks, CA: Sage; 2015. p. 379 â 409.
dc.identifier.citedreferenceLiu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001; 134 ( 10 ): 968 â 77.
dc.identifier.citedreferenceHaberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013; 10 ( 9 ): 1001511.
dc.identifier.citedreferenceGengiah TN, Upfold M, Naidoo A, Mansoor LE, Feldblum PJ, Abdool Karim Q, et al. Monitoring microbicide gel use with realâ time notification of the container’s opening events: results of the CAPRISA Wisebag study. AIDS Behav. 2014; 18: 833 â 40.
dc.identifier.citedreferenceMorey TE, Wasdo S, Wishin J, Quinn B, van der Straten A, Booth M, et al. Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol. 2012; 53: 101 â 11.
dc.identifier.citedreferenceWorld Health Organization, UNAIDS, UNICEF. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Geneva, Switzerland: 2011.
dc.identifier.citedreferenceBeyrer C, Abdool Karim Q. The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS. 2013; 8: 306 â 10.
dc.identifier.citedreferenceTanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), National Bureau of Statistics (NBS), Office of Chief Government Statistician (OCGS), Inc. II. Tanzania HIV/AIDS and Malaria Indicator Survey. Dar es Salaam, Tanzania: 2011 â 12.
dc.identifier.citedreferenceMmbaga EJ, Leonard F, Leyna GH. Incidence and predictors of adolescent’s early sexual debut after three decades of HIV interventions in Tanzania: a time to debut analysis. PLoS One. 2012; 7: e41700.
dc.identifier.citedreferenceImanguli N. Youth and the global HIV/AIDS pandemic. Washington, DC: Advocates for Youth; 2008.
dc.identifier.citedreferenceMaman S, Mbwambo JK, Hogan NM, Kilonzo GP, Campbell JC, Weiss E, et al. HIVâ positive women report more lifetime partner violence: findings from a voluntary counseling and testing clinic in Dar es Salaam, Tanzania. Am J Public Health. 2002; 92: 1331 â 7.
dc.identifier.citedreferenceMaganja RK, Maman S, Groves A, Mbwambo JK. Skinning the goat and pulling the load: transactional sex among youth in Dar es Salaam, Tanzania. AIDS Care. 2007; 19: 974 â 81.
dc.identifier.citedreferenceYamanis TJ, Doherty IA, Weir SS, Bowling JM, Kajula LJ, Mbwambo JK, et al. From coitus to concurrency: sexual partnership characteristics and risk behaviors of 15â 19 year old men recruited from urban venues in Tanzania. AIDS Behav. 2013; 17: 2405 â 15.
dc.identifier.citedreferenceUrassa W, Moshiro C, Chalamilla G, Mhalu F, Sandstrom E. Risky sexual practices among youth attending a sexually transmitted infection clinic in Dar es Salaam, Tanzania. BMC Infect Dis. 2008; 8: 159.
dc.identifier.citedreferenceDesai J, Katz K, Janowitz B. Iringa Youth Behavioral Survey: findings and report. Research Triangle Park, NC: Family Health International; 2005.
dc.identifier.citedreferenceAbdool Karim Q, Kharsany ABM, Frohlich JA, Werner L, Mlotshwa M, Madlala BT, et al. HIV incidence in young girls in KwaZuluâ Natal, South Africaâ public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav. 2012; 16: 1870 â 6.
dc.identifier.citedreferenceSkolerâ Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, doubleâ blind, placeboâ controlled trial. Lancet. 2008; 372: 1977 â 87.
dc.identifier.citedreferenceNunn A, McCormack S, Crook AM, Pool R, Rutterford C, Hayes R. Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials. 2009; 10: 99.
dc.identifier.citedreferenceRossi L. Understanding the results of VOICE2013. [cited 2014 Aug 11]. Available from: http://www.mtnstopshiv.org/sites/default/files/attachments/UnderstandingVOICEresults_FINAL.pdf.
dc.identifier.citedreferenceDiClemente RJ, Ruiz MS, Sales JM. Barriers to adolescentsâ participation in HIV biomedical prevention research. J Acquir Immune Defic Syndr. 2010; 54 (Suppl 1 ): S12 â 7.
dc.identifier.citedreferenceMacQueen KM, Karim QA. Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses in AIDS Care: JANAC. 2007; 18: 78 â 82.
dc.identifier.citedreferencePomfret S, Abdool Karim Q, Benatar SR. Barriers to adolescentsâ participation in HIV biomedical prevention research. J Acquir Immune Defic Syndr. 2010; 54: S12 â 7.
dc.identifier.citedreferenceEssack Z, Slack C, Strode A. Overcoming key obstacles to adolescent involvement in HIV vaccine & microbicide trials: a roadmap for stakeholders. HIV AIDS Vaccines Ethics Group in collaboration with the Global Campaign for Microbicides, 2008.
dc.identifier.citedreferenceJaspan HB, Berwick JR, Myer L, Mathews C, Flisher AJ, Wood R, et al. Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J Adolesc Health. 2006; 39: 642 â 8.
dc.identifier.citedreferenceUlin PR, Robinson ET, Tolley EE. Qualitative methods in public health: a field guide for applied research. Indianapolis: Josseyâ Bass; 2006. 300 p.
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. New Engl J Med. 2012; 367: 411 â 22.
dc.identifier.citedreferenceMiddelkoop K, Myer L, Mark D, Mthimunye SP, Smit J, Wood R, et al. Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa. J Adolesc Health. 2008; 43: 8 â 14.
dc.identifier.citedreferenceSchenk KD, Friedland BA, Chau M, Stoner M, Plagianos MG, Skolerâ Karpoff S, et al. Enrollment of adolescents aged 16â 17 years old in microbicide trials: an evidenceâ based approach. J Adolesc Health. 2014; 54: 654 â 62.
dc.identifier.citedreferenceNational AIDS and STI Control Programme. Kenya AIDS indicator survey 2012: preliminary report. Nairobi, Kenya: Ministry of Health; 2013.
dc.identifier.citedreferenceNational AIDS and STI Control Programme. Kenya AIDS indicator survey 2007. Nairobi, Kenya: Ministry of Health; 2008.
dc.identifier.citedreferenceCelum C. HIV preexposure prophylaxis: new data and potential use. Top Antivir Med. 2011; 19: 181 â 5.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 ( 5 ): 399 â 410.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 ( 27 ): 2587 â 99.
dc.identifier.citedreferenceKarim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferenceLiu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, et al. Early experiences implementing preâ exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014; 11 ( 3 ): e1001613.
dc.identifier.citedreferenceBecker J, Dabash R, McGory E, Copper D, Harries J, Hoffman M, et al. Paving the path: preparing for microbicide introduction report of a qualitative study in South Africa. New York: EngenderHealth; 2004.
dc.identifier.citedreferenceNgugi E, Benoit C, Hallgrimsdottir H, Jansson M, Roth EA. Partners and clients of female sex workers in an informal urban settlement in Nairobi, Kenya. Cult Health Sex. 2012; 14 ( 1 ): 17 â 30.
dc.identifier.citedreferenceGreene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among highâ risk women in Africa and India. Cult Health Sex. 2010; 12 ( 7 ): 739 â 54.
dc.identifier.citedreferenceBenkiâ Nugent S, Chung MH, Ackers M, Richardson BA, McGrath CJ, Kohler P, et al. Knowing a sexual partner is HIVâ 1â uninfected is associated with higher condom use among HIVâ 1â infected adults in Kenya. Sex Transm Dis. 2011; 38 ( 9 ): 808 â 10.
dc.identifier.citedreferenceLuke N, Goldberg RE, Mberu BU, Zulu EM. Social exchange and sexual behavior in young women’s premarital relationships in Kenya. J Marriage Fam. 2011; 73 ( 5 ): 1048 â 64.
dc.identifier.citedreferenceUNFPA. HIV prevention gains momentum: successes in female condom programming. New York, NY: UNFPA; 2011.
dc.identifier.citedreferenceMontgomery CM, Lees S, Stadler J, Morar NS, Ssali A, Mwanza B, et al. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care. 2008; 20 ( 6 ): 733 â 40.
dc.identifier.citedreferenceChiao C, Mishra V, Ksobiech K. Spousal communication about HIV prevention in Kenya. J Health Commun. 2011; 16 ( 10 ): 1088 â 105.
dc.identifier.citedreferenceMcClelland L, Wanje G, Kashonga F, Kibe L, McClelland RS, Kiarie J, et al. Understanding the context of HIV risk behavior among HIVâ positive and HIVâ negative female sex workers and male bar clients following antiretroviral therapy rollout in Mombasa, Kenya. AIDS Educ Prev. 2011; 23 ( 4 ): 299 â 312.
dc.identifier.citedreferenceWestercamp N, Mattson CL, Madonia M, Moses S, Agot K, Ndinyaâ Achola JO. Determinants of consistent condom use vary by partner type among young men in Kisumu, Kenya: a multiâ level data analysis. AIDS Behav. 2010; 14 ( 4 ): 949 â 59.
dc.identifier.citedreferenceMatovu JK, Ssebadduka BN. Sexual risk behaviours, condom use and sexually transmitted infection treatmentâ seeking behaviours among female sex workers and truck drivers in Uganda. Int J STD AIDS. 2012; 23 ( 4 ): 267 â 73.
dc.identifier.citedreferenceNational AIDS and STI Control Programme. Mostâ atâ risk populations: unveiling new evidence for accelerated programming in MARPS surveillance report. Nairobi, Kenya: Ministry of Health; 2012.
dc.identifier.citedreferenceOkal J, Chersich MF, Tsui S, Sutherland E, Temmerman M, Luchters S. Sexual and physical violence against female sex workers in Kenya: a qualitative enquiry. AIDS Care. 2011; 23 ( 5 ): 612 â 8.
dc.identifier.citedreferenceFIDA Kenya, The Federation of Women Lawyers. Documenting human rights violation of sex workers in Kenya. 2008 [cited 2012 Apr 10]. Available from: http://kelinkenya.org/wpâ content/uploads/2010/10/Documentingâ Humanâ Rightsâ Violationsâ ofâ Sexâ Workers.pdf
dc.identifier.citedreferenceOchako R, Ulwodi D, Njagi P, Kimetu S, Onyango A. Trends and determinants of comprehensive HIV and AIDS knowledge among urban young women in Kenya. AIDS Res Ther. 2011; 8: 11.
dc.identifier.citedreferenceThomsen SC, Ombidi W, Toroitichâ Ruto C, Wong EL, Tucker HO, Homan R, et al. A prospective study assessing the effects of introducing the female condom in a sex worker population in Mombasa, Kenya. Sex Transm Infect. 2006; 82 ( 5 ): 397 â 402.
dc.identifier.citedreferenceTegang SP, Abdallah S, Emukule G, Luchters S, Kingola N, Barasa M. Concurrent sexual and substanceâ use risk behaviours among female sex workers in Kenya’s Coast Province: findings from a behavioural monitoring survey. SAHARA J. 2010; 7 ( 4 ): 10 â 6.
dc.identifier.citedreferenceOkal J, Luchters S, Geibel S, Chersich MF, Lango D, Temmerman M. Social context, sexual risk perceptions and stigma: HIV vulnerability among male sex workers in Mombasa, Kenya. Cult Health Sex. 2009; 11 ( 8 ): 811 â 26.
dc.identifier.citedreferenceBukusi EA, Gallo MF, Sharma A, Njoroge B, Jamieson DJ, Nguti R, et al. Adherence to diaphragm use for infection prevention: a prospective study of female sex workers in Kenya. Infect Dis Obstet Gynecol. 2009; 2009: 420196.
dc.identifier.citedreferenceHawken MP, Melis RDJ, Ngombo DT, Mandaliya K, Price J, Dallabetta G, et al. Part time female sex workers in a suburban community in Kenya: a vulnerable hidden population. Sex Transm Infect. 2002; 78 ( 4 ): 271 â 3.
dc.identifier.citedreferencePriddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, et al. Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. AIDS Res Hum Retroviruses. 2011; 27 ( 10 ): 1067 â 72.
dc.identifier.citedreferenceSmith DJ, Wakasiaka S, Hoang TD, Bwayo JJ, Del Rio C, Priddy FH. An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a highâ risk population. J Womens Health (Larchmt). 2008; 17 ( 6 ): 1025 â 34.
dc.identifier.citedreferenceNational AIDS Control Council. Kenya HIV prevention response and modes of transmission analysis. Nairobi, Kenya: National AIDS Control Council; 2009.
dc.identifier.citedreferenceTaegtmeyer M, Kilonzo N, Mung’ala L, Morgan G, Theobald S. Using gender analysis to build voluntary counselling and testing responses in Kenya. Trans R Soc Trop Med Hyg. 2006; 100 ( 4 ): 305 â 11.
dc.identifier.citedreferenceAkwara PA, Madise NJ, Hinde A. Perception of risk of HIV/AIDS and sexual behaviour in Kenya. J Biosoc Sci. 2003; 35 ( 3 ): 385 â 411.
dc.identifier.citedreferenceKaiser R, Bunnell R, Hightower A, Kim AA, Cherutich P, Mwangi M, et al. Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. PLoS One. 2011; 6 ( 3 ): e17842.
dc.identifier.citedreferenceMuturi NW. Communication for HIV/AIDS prevention in Kenya: socialâ cultural considerations. J Health Commun. 2005; 10 ( 1 ): 77 â 98.
dc.identifier.citedreferenceMiller AN, Golding L, Ngula KW, Wambua M, Mutua E, Kitizo MN. Couplesâ communication on sexual and relational issues among the Akamba in Kenya. Afr J AIDS Res. 2009; 8 ( 1 ): 51 â 60.
dc.identifier.citedreferenceNeville AN, Rubin DL. Factors leading to selfâ disclosure of a positive HIV diagnosis in Nairobi, Kenya: people living with HIV/AIDS in the Subâ Sahara. Qual Health Res. 2007; 17 ( 5 ): 586 â 98.
dc.identifier.citedreferenceKenya National Bureau of Statistics, ICF Macro. Kenya demographic and health survey 2008â 09. Calverton, MD: KNBS; 2010.
dc.identifier.citedreferenceSarna A, Chersich M, Okal J, Luchters SM, Mandaliya KN, Rutenberg N, et al. Changes in sexual risk taking with antiretroviral treatment: influence of context and gender norms in Mombasa, Kenya. Cult Health Sex. 2009; 11 ( 8 ): 783 â 97.
dc.identifier.citedreferenceWere E, Woolsâ Kaloustian K, Baliddawa J, Ayuo PO, Sidle J, Fife K. Stakeholders perception of HIV seroâ discordant couples in western Kenya. East Afr Med J. 2008; 85 ( 7 ): 326 â 33.
dc.identifier.citedreferenceAwiti Ujiji O, Ekström AM, Ilako F, Indalo D, Wamalwa D, Rubenson B. Reasoning and deciding PMTCTâ adherence during pregnancy among women living with HIV in Kenya. Cult Health Sex. 2011; 13 ( 7 ): 829 â 40.
dc.identifier.citedreferenceMiller NA, Rubin DL. Factors leading to selfâ disclosure of a positive HIV diagnosis in Nairobi, Kenya: people living with HIV/AIDS in the Subâ Sahara. Qual Health Res. 2007; 17 ( 5 ): 586 â 98.
dc.identifier.citedreferenceMatickaâ Tyndale E, Kyeremeh C. The trouble with condoms: norms and meanings of sexuality and condom use among schoolâ going youth in Kenya. Int J Sex Health. 2010; 22 ( 4 ): 234 â 47.
dc.identifier.citedreferenceNjue C, Voeten HA, Remes P. Porn video shows, local brew, and transactional sex: HIV risk among youth in Kisumu, Kenya. BMC Public Health. 2011; 11 ( 1 ): 635.
dc.identifier.citedreferenceKabiru CW, Luke N, Izugbara CO, Zulu EM. The correlates of HIV testing and impacts on sexual behavior: evidence from a life history study of young people in Kisumu, Kenya. BMC Public Health. 2010; 10: 412.
dc.identifier.citedreferenceNgom P, Magadi M, Owuor T. Parental presence and adolescent reproductive health among the Nairobi urban poor. J Adolesc Health. 2003; 33 ( 5 ): 369 â 77.
dc.identifier.citedreferenceLongfield K, Glick A, Waithaka M, Berman J. Relationships between older men and younger women: implications for STIs/HIV in Kenya. Stud Fam Plann. 2004; 35 ( 2 ): 125 â 34.
dc.identifier.citedreferenceMatickaâ Tyndale E, Gallant M, Brouillardâ Coyle C, Holland D, Metcalfe K, Wildish J, et al. The sexual scripts of Kenyan young people and HIV prevention. Cult Health Sex. 2005; 7 ( 1 ): 27 â 41.
dc.identifier.citedreferenceNzioka C. Perspectives of adolescent boys on the risks of unwanted pregnancy and sexually transmitted infections: Kenya. Reprod Health Matters. 2001; 9 ( 17 ): 108 â 17.
dc.identifier.citedreferenceMontandon M, Sahinâ Hodoglugil NN, Bukusi E, Agot K, Boland B, Cohen CR. Sexuality, HIV risk and potential acceptability of involving adolescent girls in microbicide research in Kisumu, Kenya. Sex Health. 2008; 5 ( 4 ): 339 â 46.
dc.identifier.citedreferenceNjue C, Voeten HA, Remes P. Disco funerals: a risk situation for HIV infection among youth in Kisumu, Kenya. AIDS. 2009; 23 ( 4 ): 505 â 9.
dc.identifier.citedreferenceWarenius L. Sexual and reproductive health services for young people in Kenya and Zambia. Stockholm, Sweden: Published by Karolinska Institutet; 2008.
dc.identifier.citedreferencePapo JK, Bauni EK, Sanders EJ, Brocklehurst P, Jaffe HW. Exploring the condom gap: is supply or demand the limiting factor â condom access and use in an urban and a rural setting in Kilifi district, Kenya. AIDS. 2011; 25 ( 2 ): 247 â 55.
dc.identifier.citedreferenceUNAIDS. Social marketing: an effective tool in the global response to HIV/AIDS. Washington, DC: Population Services International; 1998.
dc.identifier.citedreferencePopulation Services International. The social marketing evidence base. 2010 [cited 2014 June 16]. Available from: http://www.psi.org/resources/socialâ marketingâ evidenceâ base/socialâ marketingâ evidenceâ base
dc.identifier.citedreferenceTombros A. Integrating efforts to prevent HIV, other STIs, and pregnancy among teens in developing countries. Washington, DC: Advocates for Youth; 2005.
dc.identifier.citedreferencePerson AK, Hicks CB. Preâ exposure prophylaxis â one more tool for HIV prevention. Curr HIV Res. 2012; 10 ( 2 ): 117 â 22.
dc.identifier.citedreferenceBaeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS. 2012; 7 ( 6 ): 514 â 9.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 ( 27 ): 2587 â 99.
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367 ( 5 ): 411 â 22.
dc.identifier.citedreferencevan der Straten A, van Damme L, Haberer JE, Bangsberg DR. How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS. 2012; 26 ( 7 ): F13 â 9. DOI: 10.1097/QAD.0b013e3283522272.
dc.identifier.citedreferenceMarrazzo JM, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preâ exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3â 6; Atlanta, GA. Abstract 26LB.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferenceRoss J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982â 2009. Glob Health Sci Pract. 2013; 1 ( 2 ): 203 â 12.
dc.identifier.citedreferenceFrost J, Darroch J. Factors associated with contraceptive choice and inconsistent method use, United States, 2004. Perspect Sex Reprod Health. 2008; 40 ( 2 ): 94 â 104.
dc.identifier.citedreferenceGray A, Smit J, Manzini N, Beksinska M. Systematic review of contraceptive medicines. â Does choice make a difference?â [Internet] 2006. [cited 2014 Aug 14]. Available from: http://archives.who.int/eml/expcom/expcom15/applications/sections/ContraChoiceReview.pdf
dc.identifier.citedreferenceNodin N, Carballoâ Dieguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bioâ medical products among MSM who bareback. AIDS Care. 2008; 20 ( 1 ): 106 â 15.
dc.identifier.citedreferenceHeffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, et al. Willingness of Kenyan HIVâ 1 serodiscordant couples to use antiretroviral based HIVâ 1 prevention strategies. J Acquir Immune Defic Syndr. 2012; 61 ( 1 ): 116 â 9.
dc.identifier.citedreferenceGalea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of preâ exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to preâ exposure prophylaxis uptake among atâ risk Peruvian populations. Int J STD AIDS. 2011; 22 ( 5 ): 256 â 62.
dc.identifier.citedreferenceLiu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, Matheson T, et al. Limited knowledge and use of HIV postâ and preâ exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008; 47 ( 2 ): 241 â 7.
dc.identifier.citedreferenceMimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in highâ risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009; 50 ( 1 ): 77 â 83.
dc.identifier.citedreferenceGolub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among highâ risk men who have sex with men. J Acquir Immune Defic Syndr. 2010; 54 ( 5 ): 548 â 55.
dc.identifier.citedreferenceDunkle K, Wingood G, Camp C, DiClemente R. Intention to use preexposure prophylaxis among Africanâ American and white women in the United States: results from a national telephone survey. AIDS 2008 â XVII International AIDS Conference; Mexico City; 2008. Abstract no. WEPE0258.
dc.identifier.citedreferencevan der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV preâ exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in atâ risk populations in Kenya. AIDS Behav. 2013; 17 ( 6 ): 2162 â 72.
dc.identifier.citedreferenceWare NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral preâ exposure prophylaxis for HIVâ serodiscordant couples. J Acquir Immune Defic Syndr. 2012; 59 ( 5 ): 463 â 8.
dc.identifier.citedreferenceBrooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV preâ exposure prophylaxis among HIVâ negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS. 2012; 26 ( 2 ): 87 â 94.
dc.identifier.citedreferenceTerrisâ Prestholt F, Hanson K, MacPhail C, Vickerman P, Rees H, Watts C. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One. 2013; 8 ( 12 ): e83193.
dc.identifier.citedreferenceGreene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among highâ risk women in Africa and India. Cult Health Sex. 2010; 12 ( 7 ): 739 â 54.
dc.identifier.citedreferenceRupp RE, Rosenthal SL. Vaginal microbicides and teenagers. Curr Opin Obstet Gynecol. 2003; 15 ( 5 ): 371 â 5.
dc.identifier.citedreferenceShattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med. 2012; 2 ( 2 ): a007385.
dc.identifier.citedreferenceMartin Hilber A, Hull TH, Prestonâ Whyte E, Bagnol B, Smit J, Wacharasin C, et al. A cross cultural study of vaginal practices and sexuality: implications for sexual health. Soc Sci Med. 2010; 70 ( 3 ): 392 â 400.
dc.identifier.citedreferenceKarim QA, Baxter C, Karim SA. Topical microbicidesâ what’s new? J Acquir Immune Defic Syndr. 2013; 63 (Suppl 2 ): S144 â 9.
dc.identifier.citedreferenceWoodsong C, Karim QA. A model designed to enhance informed consent: experiences from the HIV prevention trials network. Am J Public Health. 2005; 95 ( 3 ): 412 â 9.
dc.identifier.citedreferenceUNAIDS. Global report â UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS, Geneva; 2013.
dc.identifier.citedreferenceHouts PS, Doak CC, Doak LG, Loscalzo MJ. The role of pictures in improving health communication: a review of research on attention, comprehension, recall, and adherence. Patient Educ Couns. 2006; 61 ( 2 ): 173 â 90.
dc.identifier.citedreferencePeregrin T. Picture this: visual cues enhance health education messages for people with low literacy skills. J Am Diet Assoc. 2010; 110 (Suppl 5 ): S28 â 32.
dc.identifier.citedreferenceStrauss R, Sengupta S, Quinn SC, Goeppinger J, Spaulding C, Kegeles SM, et al. The role of community advisory boards: involving communities in the informed consent process. Am J Public Health. 2001; 91: 1938 â 43.
dc.identifier.citedreferenceMorin SF, Maiorana A, Koester KA, Sheon NM, Richards TA. Community consultation in HIV prevention research: a study of community advisory boards at 6 research sites. J Acquir Immune Defic Syndr. 2003; 33 ( 4 ): 513 â 20.
dc.identifier.citedreferenceQuinn SC. Ethics in public health research: protecting human subjects: the role of community advisory boards. Am J Public Health. 2004; 94 ( 6 ): 918 â 22.
dc.identifier.citedreferenceMacQueen K. Stakeholder engagement and good participatory practices for global clinical trials: developing tools and models for the 21st century. Presented at the 20th International AIDS Conference, 2014 Jul 20â 25, Melbourne, Australia; 2014.
dc.identifier.citedreferenceAbdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011; 25 ( 7 ): 957 â 66.
dc.identifier.citedreferenceIPM. IPM 027 IPM 027. 2012 [cited 2014 Aug 11]. Available from: http://www.ipmglobal.org/ourâ work/research/ipmâ 027â ringâ studyâ 0
dc.identifier.citedreferenceMacQueen KM, Alleman P. International perspectives on the collection, storage, and testing of human biospecimens in HIV research. IRB. 2008; 30 ( 4 ): 9 â 14.
dc.identifier.citedreferenceStadler J, Eirik S. Rumours about blood and reimbursements in a microbicide gel trial. Afr J AIDS Res. 2010; 9 ( 4 ): 345 â 53.
dc.identifier.citedreferenceFairhead J, Leach M, Small M. Where technoâ science meets poverty: medical research and the economy of blood in The Gambia, West Africa. Soc Sci Med. 2006; 63 ( 4 ): 1109 â 20.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367: 399 â 410.
dc.identifier.citedreferenceBerger RE. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. J Urol. 2011; 185: 1729.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587 â 99.
dc.identifier.citedreferenceKarim SSA, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preâ exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011; 378: 279 â 81.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367: 423 â 34.
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367: 411 â 22.
dc.identifier.citedreferenceMarrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito Taljaard M, et al. Preâ exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). San Francisco, CA: CROI Foundation; 2013.
dc.identifier.citedreferenceBraunstein S, van de Wijgert J. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health (Larchmt). 2005; 14: 424 â 33.
dc.identifier.citedreferenceKoblin BA, Andrasik M, Austin J. Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions. J Acquir Immune Defic Syndr. 2013; 63 (Suppl 2 ): S183 â 6.
dc.identifier.citedreferenceRausch DM, Grossman CI, Erbelding EJ. Integrating behavioral and biomedical research in HIV interventions: challenges and opportunities. J Acquir Immune Defic Syndr. 2013; 63 Suppl 1: S6 â 11.
dc.identifier.citedreferenceStirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008; 5: 186 â 92.
dc.identifier.citedreferenceTolley EE, Severy LJ. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health. 2006; 96: 79 â 83.
dc.identifier.citedreferenceTerrisâ Prestholt F, Hanson K, MacPhail C, Vickerman P, Rees H, Watts C. How much demand for new HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One. 2013; 8: e83193.
dc.identifier.citedreferenceBentley ME, Morrow KM, Fullem A, Chesney MA, Horton SD, Rosenberg Z, et al. Acceptability of a novel vaginal microbicide during a safety trial among lowâ risk women. Fam Plan Perspect. 2000; 32 ( 4 ): 184 â 8.
dc.identifier.citedreferenceBentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, et al. Acceptability of a microbicide among women and their partners in a 4â country phase I trial. Am J Public Health. 2004; 94: 1159 â 64.
dc.identifier.citedreferenceGreene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among highâ risk women in Africa and India. Cult Health Sex. 2010; 12: 739 â 54.
dc.identifier.citedreferenceMorrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO Gel, among women in a phase I clinical trial. J Women’s Health (2002). 2003; 12: 655 â 66.
dc.identifier.citedreferenceReiff M, Wade C, Chao MT, Kronenberg F, Cushman LF. Health practices and vaginal microbicide acceptability among urban black women. J Womens Health (Larchmt). 2008; 17: 1345 â 51.
dc.identifier.citedreferenceRosen RK, Morrow KM, Carballoâ Diéguez A, Mantell JE, Hoffman S, Gai F, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixedâ methods study. J Women’s Health (2002). 2008;17: 383 â 92.
dc.identifier.citedreferenceWeeks MR, Mosack KE, Abbott M, Sylla LN, Valdes B, Prince M. Microbicide acceptability among highâ risk urban U.S. women: experiences and perceptions of sexually transmitted HIV prevention. Sex Transm Dis. 2004; 31: 682 â 90.
dc.identifier.citedreferenceMngadi K, Maarschalk S, Grobler A, Mansoor L, Frohlich J, Madlala B, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014; 18 ( 5 ): 849 â 54.
dc.identifier.citedreferenceMansoor L, Karim Q, Werner L, Madlala B, Ngcobo N, Cornman D, et al. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav. 2014; 18 ( 5 ): 841 â 8.
dc.identifier.citedreferenceMorrow KM, Fava JL, Rosen RK, Vargas S, Shaw JG, Kojic EM, et al. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses [Internet]. 2013 [cited 2014 Jun 20]. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=24180360
dc.identifier.citedreferencevan den Berg JJ, Rosen RK, Bregman DE, Thompson LA, Jensen KM, Kiser PF, et al. â Set it and forget itâ : women’s perceptions and opinions of longâ acting topical vaginal gels. AIDS Behav. 2014; 18: 862 â 70.
dc.identifier.citedreferenceGafos M, Mzimela M, Sukazi S, Pool R, Montgomery C, Elford J. Intravaginal insertion in KwaZuluâ Natal: sexual practices and preferences in the context of microbicide gel use. Cult Health Sex. 2010; 12: 929 â 42.
dc.identifier.citedreferenceHall P. IDEO takes on the government. Metropolis. 2011. p. 100 â 10.
dc.identifier.citedreferenceJahnke M. Innovation through design thinking. Business. 2009; 44: 1 â 26.
dc.identifier.citedreferenceBrown T, Wyatt J. Design thinking for social innovation. Stanford Soc Innovat Rev. 2010; 8: 30 â 5.
dc.identifier.citedreferenceBrown T. Design thinking. Harv Bus Rev. 2008; 86: 84 â 92, 141.
dc.identifier.citedreferenceBuchenau M, Francisco IS, Suri JF. Experience prototyping. Conference on Designing Interactive Systems: Processes, Practices, Methods, and Techniques. San Francisco, CA: IDEO; 2000. p. 424 â 33.
dc.identifier.citedreferenceWhatmore J. The art of innovation: success through innovation the IDEO way. Long Range Plan. 2001; 34: 625.
dc.identifier.citedreferenceSuri JF, Howard SG. Going deeper, seeing further: enhancing ethnographic interpretations to reveal more meaningful opportunities for design. J Advert Res. 2006; 46: 246 â 50.
dc.identifier.citedreferenceMadsbjerb C, Rasmussen M. The moment of clarity: using the human sciences to solve your toughest business problems. Boston, Massachusetts: Harvard Business Review Press; 2014.
dc.identifier.citedreferenceSigall H, Aronson E, van Hoose T. The cooperative subject: Myth or reality? J Exp Soc Psychol. 1970; 6: 1 â 10.
dc.identifier.citedreferenceWang C, Burris MA. Photovoice: concept, methodology, and use for participatory needs assessment. Health Educ Behav. 1997; 24: 369 â 87.
dc.identifier.citedreferenceWang CC. Photovoice: a participatory action research strategy applied to women’s health. J Womens Heal Off Publ Soc Adv Womens Heal Res. 1999; 8: 185 â 92.
dc.identifier.citedreferenceIrwin R. IDEO’s design cure: can it fix our sick healthâ care system? Metropolis. San Francisco, CA: Reprinted by IDEO; 2002. Available from: http://www.ideo.com/images/uploads/news/pdfs/metropolis_1.pdf.
dc.identifier.citedreferenceShah A, Thathachari J, Agarwal R, Karamchandani A. A market led, evidence based, approach to rural sanitation [Internet]. 2013 [cited 2014 Jun 20]. Available from: https://s3.amazonaws.com/static.water.org/watercredit/Market+Led+Approach+to+Rural+Sanitation+(Monitor+Inclusive+Markets)â 1.pdf
dc.identifier.citedreferenceWorld Health Organization. WHO handbook for guideline development. Geneva, Switzerland: World Health Organization; 2012.
dc.identifier.citedreferenceGuyatt GH, Oxman AD, Vist GE, Kunz R, Falckâ Ytter Y, Alonsoâ Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J. 2008; 336 ( 7650 ): 924 â 6.
dc.identifier.citedreferenceWorld Health Organization. Ensuring human rights in the provision of contraceptive information and services: guidance and recommendations. Geneva, Switzerland: World Health Organization; 2014.
dc.identifier.citedreferencePlan of Action of the International Conference on Population and Development [Internet]. 1994 [cited 2014 Jun 17]. Available from: http://www.un.org/popin/icpd/conference/offeng/poa.html
dc.identifier.citedreferenceFourth World Conference on Women. Beijing Declaration and Platform for Action [Internet]. 1995 [cited 2014 Jun 17]. Available from: http://www.un.org/womenwatch/daw/beijing/platform/
dc.identifier.citedreferenceWorld Health Organization. Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets. Geneva, Switzerland: World Health Organization; 2004. Report No.: WHO/RHR/04.8.
dc.identifier.citedreferenceThe President’s Emergency Plan for AIDS Relief. Updated gender strategy [Internet]. 2013 [cited 2014 Jun 17]. Available from: http://www.pepfar.gov/documents/organization/219117.pdf
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367: 411 â 22.
dc.identifier.citedreferenceMarrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preâ exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003) (Paper #26LB). 20th Conference on Retorviruses and Opportunistic Infections. Georgia World Conference Center, Atlanta; 2013.
dc.identifier.citedreferenceGray GE, Allen M, Moodie Z, Churchyard G, Bekker Lâ G, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a cladeâ Bâ based HIVâ 1 vaccine in South Africa: a doubleâ blind, randomised, placeboâ controlled testâ ofâ concept phase 2b study. Lancet Infect Dis. 2011; 11 ( 7 ): 507 â 15.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferenceWeller SC, Davisâ Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database of Syst Rev. 2002; 1: CD003255.
dc.identifier.citedreferenceRojanapithayakorn W. The 100% condom use programme in Asia. Reprod Health Matters. 2006; 14 ( 28 ): 41 â 52.
dc.identifier.citedreferenceFoss AM, Watts CH, Vickerman P, Heise L. Condoms and prevention of HIV. Br Med J. 2004; 329 ( 7459 ): 185 â 6.
dc.identifier.citedreferenceCleland J, Ali MM, Shah I. Trends in protective behaviour among single vs. married young women in subâ Saharan Africa: the big picture. Reprod Health Matters. 2006; 14 ( 28 ): 17 â 22.
dc.identifier.citedreferenceFACTS Consortium. FACTS001 study [Internet]. 2013 [cited 2013 May 15]. Available from: http://www.factsâ consortium.co.za/
dc.identifier.citedreferenceInternational Partnership for Microbicides. Dapivirine microbicide ring [cited 2012 Apr 26]. Available from: http://www.ipmglobal.org/node/532
dc.identifier.citedreferenceMicrobicide Trials Network. Phase III trial of dapivirine ring begins in Africa: ASPIRE testing new HIV prevention approach for women [Internet]. 2012 [cited 2013 May 15]. Available from: http://www.mtnstopshiv.org/node/4546
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 ( 27 ): 2587 â 99.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 ( 5 ): 399 â 410.
dc.identifier.citedreferenceChoopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, doubleâ blind, placeboâ controlled phase 3 trial. Lancet. 2013; 381 ( 9883 ): 2083 â 90.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367 ( 5 ): 423 â 34.
dc.identifier.citedreferenceWHO. Guidance on oral preâ exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV [Internet]. 2012 [cited 2014 Jun 17]. Available from: http://www.who.int/hiv/pub/guidance_prep/en/
dc.identifier.citedreferenceAVAC. Ongoing and planned PrEP trials and demonstration projects [Internet]. 2013 [cited 2014 Jun 17]. Available from: http://www.prepwatch.org/wpâ content/uploads/2014/01/PrEPâ Trialsâ andâ Demoâ Projectsâ Decemberâ 2013.pdf
dc.identifier.citedreferenceWorld Health Organization. Meeting report on stakeholder consultation on priority implementation research to inform development of WHO normative guidance on topical preâ exposure prophylaxis. 2014. Geneva, Switzerland: World Health Organization.
dc.identifier.citedreferenceHeise L, Ellsberg M, Gottemoeller M. Ending violence against women. Population reports, Series L., No. 11. Baltimore, MD: Johns Hopkins University School of Public Health, Population Information Program; 1999.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preâ exposure prophylaxis for heterosexual HIV transmission in Botswana. N Eng J Med. 2012; 367 ( 5 ): 423 â 34.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in heterosexual men and women. N Eng J Med. 2012; 367 ( 5 ): 423 â 34.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 ( 5 ): 399 â 410.
dc.identifier.citedreferenceChoopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (The Bangkok Tenofovir Study): a randomized, doubleâ blind, placeboâ controlled phase 3 trial. Lancet. 2013; 381 ( 9883 ): 2083 â 90.
dc.identifier.citedreferenceJoint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic [Internet]. 2013 Nov. ISBN 978â 92â 9173â 871â 7. [cited 2014 May 13]. Available from: http://www.refworld.org/docid/4cfca9c62.html
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367 ( 5 ): 411 â 22.
dc.identifier.citedreferenceMarrazzo J, Ramjee G, Nair G, Palance T, Mkhize B, Nakabiito C, et al. 20th Conference on Retroviruses and Opportunistic Infections. Preâ exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3â 6; Atlanta, GA.
dc.identifier.citedreferenceCorneli A, Deese J, Wang, Meng MS, Taylor D, Ahmed K, et al. Adherence patterns and factors associated with adherence to a daily oral study product for preâ exposure prophylaxis. J Acquir Immune Defic Syndr. 2014; 66 ( 3 ): 324 â 31.
dc.identifier.citedreferencevan der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery E. Perspectives on use of oral and vaginal antiretrovirals for 1 HIV prevention: the VOICEâ C study in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19146.
dc.identifier.citedreferenceCorneli A, Perry B, McKenna, K, Agot K, Ahmed K, Malamatsho F, et al. Participantsâ explanations for nonâ adherence in the FEMâ PrEP clinical trial. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA: Conference on Retroviruses and Opportunistic Infections (CROI).
dc.identifier.citedreferenceCorneli A, McKenna K, Headley J, Ahmed K, Odhiambo J, Skhosana J, et al. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEMâ PrEP participants who seroconverted in Kenya and South Africa. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19152.
dc.identifier.citedreferenceEaton L, Kalichman S. Risk compensation in HIV prevention. Curr HIV/AIDS Rep. 2007; 4 ( 4 ): 165 â 72.
dc.identifier.citedreferenceMastro T, Sista N, Abdoolâ Karim Q. ARVâ based HIV prevention for women â where are we in 2014? J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19154.
dc.identifier.citedreferenceLanham M, Wilcher R, Montgomery E, Pool R, Schuler S, Lenzi R, et al. Engaging male partners in women’s microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19159.
dc.identifier.citedreferenceThe DHS Program STAT Compiler. Fairfax, VA: ICF International [Internet]. c2012. [cited 2014 Jul 10]. Available from: http://www.statcompiler.com
dc.identifier.citedreferenceAVAC. AVAC Report 2013: research and reality. New York: AVAC; 2013.
dc.identifier.citedreferenceMacQueen K, Tolley E, Owen D, Amico R, Morrow K, Moench T, et al. An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARVâ based vaginal rings. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19158.
dc.identifier.citedreferenceTolley E, Kaaya S, Kaale A, Minja A, Bangapi D, Kalungura H, et al. Comparing patterns of sexual risk among adolescent and young women in a mixed methods study in Tanzania: implications for adolescent participation in HIV prevention trials. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19149.
dc.identifier.citedreferenceSidibe S, Pack A, Tolley E, Ryan E, Mackenzie C, Bockh E, et al. Communicating about microbicides with women in mind: Tailoring messages for specific audiences. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19151.
dc.identifier.citedreferenceMack N, Evens E, Tolley E, Brelsford K, McKenzie C, Milford C, et al. The importance of choice in the rollout of ARVâ based prevention to user groups in Kenya and South Africa: a qualitative study. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19157.
dc.identifier.citedreferenceWoodsong C, Mustambi J, Ntshele S, Modikoe P. Community and research collaboration for development of materials to inform microbicide trial participants in Africa. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19156.
dc.identifier.citedreferenceLin A, Barnhart M, Breger T, Harris E, Kim A, Vansgaard C. Learning from the private sector: towards a keener understanding of the endâ user for microbicide introduction planning. J Int AIDS Soc. 2014; 17. doi: 10.7448/ IAS.17.3.19162.
dc.identifier.citedreferenceLustiâ Narasimhan M, Khosla R, Baggaley R, Temmerman M, McGrory E, Farley T. WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical preâ exposure prophylaxis. J Int AIDS Soc. 2014; 17. doi: 10.7448/IAS.17.3.19279.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preâ exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 ( 27 ): 2587 â 99.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 ( 5 ): 399 â 410.
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preâ exposure prophylaxis for HIV infection among African women. N Engl J Med. 2012: 1 â 12.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preâ exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367 ( 5 ): 411 â 22.
dc.identifier.citedreferenceChoopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, doubleâ blind, placeboâ controlled phase 3 trial. Lancet. 2013; 381 ( 9883 ): 2083 â 90.
dc.identifier.citedreferenceMarrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofoviremtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). CROI; 2013 Mar 3â 6; Atlanta, GA; 2013.
dc.identifier.citedreferencevan der Straten A, van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of preâ exposure prophylaxis trials for HIV prevention. AIDS. 2012; 26 ( 7 ): F13 â F19. doi: 10.1097/QAD.0b013e3283522272.
dc.identifier.citedreferenceBaeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS. 2012; 7 ( 6 ): 514 â 9.
dc.identifier.citedreferenceBaeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral preâ exposure prophylaxis. Annu Rev Med. 2013; 64: 219 â 32.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferencevan der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV preâ exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in atâ risk populations in Kenya. AIDS Behav. 2012; 17 ( 6 ): 2162 â 72.
dc.identifier.citedreferenceMinnis AM, Gandham S, Richardson BA, Guddera V, Chen B, Salata R, et al. Adherence and acceptability in MTN 001: a randomized crossâ over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013; 17 ( 2 ): 737 â 47.
dc.identifier.citedreferenceMuchomba FM, Gearing RE, Simoni JM, Elâ Bassel N. State of the science of adherence in preâ exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012; 61 ( 4 ): 490 â 8.
dc.identifier.citedreferenceTangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013; 25 ( 8 ): 961 â 7.
dc.identifier.citedreferenceAmico KR, Liu A, McMahan V, Anderson PL, Lama JR, Guanira J, et al., editors. Adherence indicators and preâ exposure prophylaxis (PrEP) drug levels in the iPrEx study. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; Feb 27â Mar 2, 2011.
dc.identifier.citedreferenceAmmassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era. Antiviral Ther. 2012; 17 ( 5 ): 785 â 92.
dc.identifier.citedreferenceMunakata J, Benner JS, Becker S, Dezii CM, Hazard EH, Tierce JC. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care. 2006; 44 ( 10 ): 893 â 9.
dc.identifier.citedreferencePaterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133 ( 1 ): 21 â 30.
dc.identifier.citedreferenceGross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001; 15 ( 16 ): 2109 â 17.
dc.identifier.citedreferenceDlamini PS, Wantland D, Makoae LN, Chirwa M, Kohi TW, Greeff M, et al. HIV stigma and missed medications in HIVâ positive people in five African countries. AIDS Patient Care STDS. 2009; 23 ( 5 ): 377 â 87.
dc.identifier.citedreferenceSkhosana NL, Struthers H, Gray GE, McIntyre JA. HIV disclosure and other factors that impact on adherence to antiretroviral therapy: the case of Soweto, South Africa. Afr J AIDS Res. 2006; 5: 17 â 26.
dc.identifier.citedreferenceWare NC, Wyatt MA, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006; 18 ( 8 ): 904 â 10.
dc.identifier.citedreferenceAmbia J, Agot K. Barriers and facilitators of adherence in userâ dependent HIV prevention trials, a systematic review. Int STD Res Rev. 2013; 1 ( 1 ): 12 â 29.
dc.identifier.citedreferenceKoenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV preâ exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2013; 44 ( 1 Suppl 2 ): S91 â 8.
dc.identifier.citedreferencevan der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal preâ exposure prophylaxis: the VOICEâ C qualitative study in Johannesburg, South Africa. PLoS One. 2014; 9 ( 2 ): 89118.
dc.identifier.citedreferenceMicrobicide trials network statement on decision to discontinue use of tenofovir gel and oral tablets in VOICE, a major HIV prevention study in women. Pittsburgh, PA: Microbicide Trials Network; 2011. Available from: http://www.mtnstopshiv.org/node/3909
dc.identifier.citedreferenceMontgomery E, Stadler J, Hartmann M, Magee C, Magazi B, Mathebula F, et al., editors. Male partner roles and influence on women’s use of HIV preâ exposure prophylaxis in Johannesburg. AIDS Impact; 2013 Sep 29â Oct 3; Barcelona, Spain; 2013.
dc.identifier.citedreferenceGrelotti DJ, Closson EF, Smit JA, Mabude Z, Matthews LT, Safren SA, et al. Whoonga: potential recreational use of HIV antiretroviral medication in South Africa. AIDS Behav. 2014; 18 ( 3 ): 511 â 8.
dc.identifier.citedreferenceNiehaus IA. Death before dying: understanding AIDS stigma in the South African Lowveld. J South Afr Stud. 2007; 33: 845 â 60.
dc.identifier.citedreferenceAshforth A, Nattrass N. Ambiguities of â cultureâ and the antiretroviral rollout in South Africa. Soc Dynam. 2005; 31 ( 2 ): 285 â 303.
dc.identifier.citedreferenceGoffman E. Stigma: notes on the management of spoiled identity. Saddle Hill, NJ: Prenticeâ Hall; 1963.
dc.identifier.citedreferenceNyblade L, Singh S, Ashburn K, Brady L, Olenja J. â Once I begin to participate, people will run away from meâ : understanding stigma as a barrier to HIV vaccine research participation in Kenya. Vaccine. 2011; 29 ( 48 ): 8924 â 8.
dc.identifier.citedreferenceBaeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don’t we know? Curr HIV/AIDS Rep. 2013; 10 ( 2 ): 142 â 51.
dc.identifier.citedreferenceCastro A, Farmer P. Understanding and addressing AIDSâ related stigma: from anthropological theory to clinical practice in Haiti. Am J Public Health. 2005; 95: 53 â 9.
dc.identifier.citedreferenceChakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach. PLoS One. 2012; 7 ( 12 ): e51080.
dc.identifier.citedreferenceAbdool Karim S. Stigma impedes AIDS prevention. Nature. 2011; 474 ( 7349 ): 29 â 31.
dc.identifier.citedreferenceSchneider H, Fassin D. Denial and defiance: a socioâ political analysis of AIDS in South Africa. AIDS. 2002;16: S45 â 51.
dc.identifier.citedreferenceCorneli A, Perry B, Agot K, Ahmed K, McKenna K, Malamatsho F, et al. FEMâ PrEP: participant explanations for nonâ adherence. Conference on Retroviruses and Opportunistic Infections. MA: Boston; Mar 3â 6, 2014.
dc.identifier.citedreferenceRosenstock I. The health belief model and preventive health behavior. Health Educ Monogr. 1974; 2 ( 4 ): 354 â 86.
dc.identifier.citedreferenceRogers RW. Cognitive and physiological processes in fear appeals and attitude change: a revised theory of protection motivation. In: Cacioppo JR, Perry RE, editors. Social psychology: a sourcebook. New York: Guilford Press; 1983. p. 153 â 76.
dc.identifier.citedreferenceKowalewski MR, Henson KD, Longshore D. Rethinking perceived risk and health behavior: a critical review of HIV prevention research. Health Educ Behav. 1997; 24 ( 3 ): 313 â 25.
dc.identifier.citedreferenceGerrard M, Gibbons FX, Bushman BJ. Relation between perceived vulnerability to HIV and precautionary sexual behavior. Psychol Bull. 1996; 119 ( 3 ): 390 â 409.
dc.identifier.citedreferenceAkwara PA, Madise NJ, Hinde A. Perception of risk of HIV/AIDS and sexual behaviour in Kenya. J Biosoc Sci. 2003; 35 ( 3 ): 385 â 411.
dc.identifier.citedreferenceDo M, Meekers D. Multiple sex partners and perceived risk of HIV infection in Zambia: attitudinal determinants and gender differences. AIDS Care. 2009; 21 ( 10 ): 1211 â 21.
dc.identifier.citedreferenceMacintyre K, Rutenberg N, Brown L, Karim A. Understanding perceptions of HIV risk among adolescents in KwaZuluâ Natal. AIDS Behav. 2004; 8 ( 3 ): 237 â 50.
dc.identifier.citedreferenceMaharaj P, Cleland J. Risk perception and condom use among married or cohabiting couples in KwaZuluâ Natal, South Africa. Int Fam Plan Perspect. 2005; 31 ( 1 ): 24 â 9.
dc.identifier.citedreferenceMbizvo EM, Msuya SE, Hussain A, Chirenje MZ, Strayâ Pedersen B. HIV prevalence in Zimbabwean women: 54â 67% knowledge and perceived risk. Int J STD AIDS. 2003; 14 ( 3 ): 202 â 7.
dc.identifier.citedreferenceLindan C, Allen S, Carael M, Nsengumuremyi F, van de Perre P, Serufilira A, et al. Knowledge, attitudes, and perceived risk of AIDS among urban Rwandan women: relationship to HIV infection and behavior change. AIDS. 1991; 5 ( 8 ): 993 â 1002.
dc.identifier.citedreferenceStringer EM, Sinkala M, Kumwenda R, Chapman V, Mwale A, Vermund SH, et al. Personal risk perception, HIV knowledge and risk avoidance behavior, and their relationships to actual HIV serostatus in an urban African obstetric population. J Acquir Immune Defic Syndr. 2004; 35 ( 1 ): 60 â 6.
dc.identifier.citedreferenceMacKellar DA, Valleroy LA, Secura GM, Behel S, Bingham T, Celentano DD, et al. Perceptions of lifetime risk and actual risk for acquiring HIV among young men who have sex with men. AIDS Behav. 2007; 11 ( 2 ): 263 â 70.
dc.identifier.citedreferenceTenkorang EY, Rajulton F, Matickaâ Tyndale E. Perceived risks of HIV/AIDS and first sexual intercourse among youth in Cape Town, South Africa. AIDS Behav. 2009; 13 ( 2 ): 234 â 45.
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367 ( 5 ): 411 â 22.
dc.identifier.citedreferenceFHI 360. FHI statement on the FEMâ PrEP HIV prevention study [Internet]. 2011 [cited 2013 Dec 11]. Available from: http://www.fhi360.org/fhiâ statementâ femâ prepâ hivâ preventionâ study
dc.identifier.citedreferenceCummings GL, Battle RS, Barker JC, Krasnovsky FM. Are African American women worried about getting AIDS? A qualitative analysis. AIDS Educ Prev. 1999; 11 ( 4 ): 331 â 42.
dc.identifier.citedreferenceBrewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Metaâ analysis of the relationship between risk perception and health behavior: the example of vaccination. Health Psychol. 2007; 26 ( 2 ): 136 â 45.
dc.identifier.citedreferenceSmith KP, Watkins SC. Perceptions of risk and strategies for prevention: responses to HIV/AIDS in rural Malawi. Soc Sci Med. 2005; 60 ( 3 ): 649 â 60.
dc.identifier.citedreferencePettifor A, MacPhail C, Corneli A, Sibeko J, Kamanga G, Rosenberg N, et al. Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav. 2011; 15 ( 6 ): 1243 â 50.
dc.identifier.citedreferencevan Damme L. The FEMâ PrEP trial: TDF/FTC (Truvada®) as preâ exposure prophylaxis for HIV infection among African women. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 2012 Mar 5â 8; Seattle, WA. Abstract 32LB.
dc.identifier.citedreferenceGuest G, MacQueen KM, Namey EE. Applied thematic analysis. Washington DC: Sage; 2011.
dc.identifier.citedreferenceMcLellan E, MacQueen KM, Niedig J. Beyond the qualitative interview: data preparation and transcription. Field Methods. 2003; 15: 63 â 84.
dc.identifier.citedreferenceNVivo Qualitative Data Analysis Software. QSR International Pty Ltd; Version 9.2, 2010.
dc.identifier.citedreferenceUNAIDS. Global report: UNAIDS report on the global AIDS epidemic, 2010: regional fact sheet: Subâ Saharan Africa [Internet]. 2010 [cited 2014 Feb 24]. Available from: http://www.unaids.org/documents/20101123_FS_SSA_em_en.pdf
dc.identifier.citedreferenceKenya National Bureau of Statistics (KNBS), ICF Macro. Kenya demographic and health survey 2008â 09. Calverton, MD: KNBS; 2010.
dc.identifier.citedreferenceFestinger L. Cognitive dissonance. Sci Am. 1962; 207: 93 â 102.
dc.identifier.citedreferenceAnkomah A, Omoregie G, Akinyemi Z, Anyanti J, Ladipo O, Adebayo S. HIVâ related risk perception among female sex workers in Nigeria. HIV AIDS (Auckl). 2011; 3: 93 â 100.
dc.identifier.citedreferenceSmith KP. Why are they worried? Concern about AIDS in rural Malawi. Demogr Res. 2003; 1 ( 9 ): 279 â 318.
dc.identifier.citedreferenceAnglewicz P, Clark S. The effect of marriage and HIV risks on condom use acceptability in rural Malawi. Soc Sci Med. 2013; 97: 29 â 40.
dc.identifier.citedreferenceKrishnan S, Dunbar MS, Minnis AM, Medlin CA, Gerdts CE, Padian NS. Poverty, gender inequities, and women’s risk of human immunodeficiency virus/AIDS. Ann N Y Acad Sci. 2008; 1136: 101 â 10.
dc.identifier.citedreferenceBandali S. Norms and practices within marriage which shape gender roles, HIV/AIDS risk and risk reduction strategies in Cabo Delgado, Mozambique. AIDS Care. 2011; 23 ( 9 ): 1171 â 6.
dc.identifier.citedreferenceChimbiri AM. The condom is an â intruderâ in marriage: evidence from rural Malawi. Soc Sci Med. 2007; 64 ( 5 ): 1102 â 15.
dc.identifier.citedreferencePettifor AE, Measham DM, Rees HV, Padian NS. Sexual power and HIV risk, South Africa. Emerg Infect Dis. 2004; 10 ( 11 ): 1996 â 2004.
dc.identifier.citedreferenceJewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet. 2010; 376 ( 9734 ): 41 â 8.
dc.identifier.citedreferenceShai NJ, Jewkes R, Nduna M, Dunkle K. Masculinities and condom use patterns among young rural South Africa men: a crossâ sectional baseline survey. BMC Public Health. 2012; 12: 462.
dc.identifier.citedreferenceGreig A, Peacock D, Jewkes R, Msimang S. Gender and AIDS: time to act. AIDS. 2008; 22 (Suppl 2 ): S35 â 43.
dc.identifier.citedreferenceSmall E, Nikolova SP, Narendorf SC. Synthesizing gender based HIV interventions in Subâ Sahara Africa: a systematic review of the evidence. AIDS Behav. 2013; 17 ( 9 ): 2831 â 44.
dc.identifier.citedreferencePerry B, Oluoch L, Agot K, Taylor J, Onyango J, Ouma L, et al. Widow cleansing and inheritance among the Luo in Kenya: the need for additional womenâ centred HIV prevention options. J Int AIDS Soc. 2014; 17: 19010.
dc.identifier.citedreferenceKlein H, Elifson KW, Sterk CE. â At riskâ women who think that they have no chance of getting HIV: selfâ assessed perceived risks. Women Health. 2003; 38 ( 2 ): 47 â 63.
dc.identifier.citedreferenceBuunk BP, Dijkstra P. Rationalizations and defensive attributions for highâ risk sex among heterosexuals. Patient Educ Couns. 2001; 45 ( 2 ): 127 â 32.
dc.identifier.citedreferenceHankins C. Changes in patterns of risk. AIDS Care. 1998; 10 (Suppl 2 ): S147 â 53.
dc.identifier.citedreferenceTolley EE, Eng E, Kohli R, Bentley ME, Mehendale S, Bunce A, et al. Examining the context of microbicide acceptability among married women and men in India. Cult Health Sex. 2006; 8 ( 4 ): 351 â 69.
dc.identifier.citedreferenceFACTS Consortium. FACTS 001 study design [Internet]. Johannesburg, South Africa [cited 2013 Dec 11]. Available from: http://factsconsortium.wordpress.com/factsâ 001â study/factsâ 001â studyâ design/
dc.identifier.citedreferenceBaeten J, Palanee T. MTNâ 020: a multiâ center, randomized, doubleâ blind, placeboâ controlled phase 3 safety and effectiveness trial of a vaginal matrix ring containing dapivirine for the prevention of HIVâ 1 infection in women [Inernet]. Microbicide Trials Network (MTN); 2011 [cited 2014 Mar 17]. Available from: http://www.mtnstopshiv.org/sites/default/files/attachments/MTNâ 020%20Version1%200_28September2011_CLEAN.pdf
dc.identifier.citedreferenceInternational Partnership for Microbicides (IPM). Phase III sister studies of a microbicide ring to prevent HIV: the ring study & ASPIRE [Internet]. 2011 [cited 2014 Mar 12]. Available from: http://www.ipmglobal.org/sites/default/files/RingStudyandASPIRE_FINAL_FEBâ 2013.pdf
dc.identifier.citedreferenceDunkle KL, Jewkes R. Effective HIV prevention requires genderâ transformative work with men. Sex Transm Infect. 2007; 83 ( 3 ): 173 â 4.
dc.identifier.citedreferenceGreig FE, Koopman C. Multilevel analysis of women’s empowerment and HIV prevention: quantitative survey results from a preliminary study in Botswana. AIDS Behav. 2003; 7 ( 2 ): 195 â 208.
dc.identifier.citedreferenceHarrison A, Short SE, Tuoaneâ Nkhasi M. Reâ focusing the gender lens: caregiving women, family roles and HIV/AIDS vulnerability in Lesotho. AIDS Behav. 2014; 18 ( 3 ): 595 â 604.
dc.identifier.citedreferenceJoint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS report on the global AIDS epidemic 2013. Geneva, Switzerland: UNAIDS; 2013.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367 ( 5 ): 411 â 22.
dc.identifier.citedreferenceMarrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabilito C, et al. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtriciabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Conference on Retroviruses and Opportunistic Infections (CROI); 2013 Mar 3â 6; Atlanta, GA.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 ( 27 ): 2587 â 99.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 ( 5 ): 399 â 410.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367 ( 5 ): 423 â 34.
dc.identifier.citedreferenceChoopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, doubleâ blind, placeboâ controlled phase 3 trial. Lancet. 2013; 381 ( 9883 ): 2083 â 90.
dc.identifier.citedreferenceCohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIVâ 1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365 ( 6 ): 493 â 505.
dc.identifier.citedreferenceGrant D, Marshall K. Next steps for PrEP: getting a proven prevention option to the people who need it. New York: Gay Men’s Health Crisis, Inc; 2013.
dc.identifier.citedreferenceHendrix CW. Exploring concentration response in HIV preâ exposure prophylaxis to optimize clinical care and trial design. Cell. 2013; 155 ( 3 ): 515 â 8.
dc.identifier.citedreferenceDonnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66 ( 3 ): 340 â 8.
dc.identifier.citedreferenceAbdool Karim SS, Kashuba AD, Werner L, Abdool Karim QA. Drug concentrations after topical and oral antiretroviral preâ exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011; 378 ( 9787 ): 279 â 81.
dc.identifier.citedreferencevan der Straten A, Brown E, Marrazzo J, Chirenje Z, Gomez K, Piper J, et al. Divergent adherence estimates with pharmacokinetic and behavioral measures in VOICE (MTN003). Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferenceCorneli A, Perry B, Agot K, Ahmed K, McKenna K, Malamatsho F, et al. FEMâ PrEP: participant explanations for nonâ adherence. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferenceBaeten JM, Celum C. Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med. 2013; 368 ( 1 ): 83 â 4.
dc.identifier.citedreferenceSolomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV preâ exposure prophylaxis. AIDS. 2014; 28 ( 6 ): 851 â 9.
dc.identifier.citedreferenceMurnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIVâ 1 prevention among highâ risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013; 27 ( 13 ): 2155 â 60.
dc.identifier.citedreferenceHaberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013; 10 ( 9 ): e1001511. product for preâ exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324â 31.
dc.identifier.citedreferenceCorneli A, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEMâ PrEP: adherence patterns and factors associated with adherence to a daily, oral study
dc.identifier.citedreferenceGengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for preâ exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014; 36: 70 â 85.
dc.identifier.citedreferenceWong C, Parker C, Ahmed K, Agot K, Skhosana J, Odhiambo J, et al. Participant motivation for enrolling and continuing in the FEMâ PrEP HIV prevention clinical trial. International AIDS Society (IAS) 7th Conference on HIV Pathogenesis, Treatment and Prevention; 2013 Jun 30â Jul 3; Kuala Lumpur, Malaysia.
dc.identifier.citedreferenceAbbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIVâ 1 transmission in resourceâ limited settings. PLoS One. 2007; 2 ( 9 ): e875.
dc.identifier.citedreferenceWilliams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr. 2011; 58 ( 2 ): 207 â 10.
dc.identifier.citedreferencePretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the costâ effectiveness of preâ exposure prophylaxis (PrEP) and its impact on HIVâ 1 transmission in South Africa. PLoS One. 2010; 5 ( 11 ): e13646.
dc.identifier.citedreferenceWalensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The costâ effectiveness of preâ exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012; 54 ( 10 ): 1504 â 13.
dc.identifier.citedreferenceKashuba AD, Patterson KB, Dumond JB, Cohen MS. Preâ exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2012; 379 ( 9835 ): 2409 â 11.
dc.identifier.citedreferenceKibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV preâ exposure prophylaxis (PrEP) among HIVâ uninfected Ugandan volunteers living in HIVâ serodiscordant relationships: a randomized, clinical trial. PLoS One. 2013; 8 ( 9 ): e74314.
dc.identifier.citedreferenceChen B, Panther L, Hoesley C, Hendrix C, van der Straten A, Husnik M, et al. Safety and pharmacokinetics/pharmacodynamics of dapivirine and maraviroc vaginal rings. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferenceAVAC Report 2013: research & reality. New York: AVAC; 2013.
dc.identifier.citedreferenceBunge K, Dezzutti C, Macio I, Hendrix C, Lisa C, Rohan L, et al. FAMEâ 02: a phase I trial to assess safety, PK, and PD of gel and film formulations of dapivirine. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferenceFriend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies: products in development. Antiviral Res. 2013; 100 (Suppl): S39 â 47.
dc.identifier.citedreferenceSpreen WR, Margolis DA, Pottage JC, Jr. Longâ acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013; 8 ( 6 ): 565 â 71.
dc.identifier.citedreferenceBoffito M, Jackson A, Owen A, Becker S. New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of longâ acting injectable agents. Drugs. 2014; 74: 7 â 13.
dc.identifier.citedreferenceJackson A, Else LJ, Higgs C, Karolia Z, Khoo S, Back D, et al. Rilpivirine with darunavir/ritonavir: pharmacokinetics & safety in HIV therapyâ naïve patients. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferenceRadzio J, Spreen W, Yueh Y, Mitchell J, Jenkins L, Garciaâ Lerma J, et al. Monthly GSK744 longâ acting injections protect macaques against repeated vaginal SHIV exposures. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferenceAndrews C, Spreen W, Yueh Y, Gettie A, Russellâ Lodrigue K, Mohri H, et al. Correlating GSK1265744 plasma levels to prevention of rectal SHIV transmission in macaques. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferencePace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIVâ 1. Proc Natl Acad Sci USA. 2013; 110 ( 33 ): 13540 â 5.
dc.identifier.citedreferencePace CS, Fordyce MW, Franco D, Kao CY, Seaman MS, Ho DD. Antiâ CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIVâ 1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr. 2013; 62 ( 1 ): 1 â 9.
dc.identifier.citedreferenceHallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIVâ 1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011; 8 ( 11 ): 1001123.
dc.identifier.citedreferenceElâ Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS. 2011; 25 ( 18 ): 2295 â 9.
dc.identifier.citedreferenceDelva W, Eaton JW, Meng F, Fraser C, White RG, Vickerman P, et al. HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med. 2012; 9 ( 7 ): e1001258.
dc.identifier.citedreferenceThe HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions â towards evidenceâ based decisionâ making. PLoS Med. 2012; 9 ( 7 ): e1001259.
dc.identifier.citedreferenceWorld Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO; 2013.
dc.identifier.citedreferencePhillips A. MSM in the UK: prevention effects of ART in perspective. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 6; Boston, MA.
dc.identifier.citedreferenceTanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZuluâ Natal, South Africa. Science. 2013; 339 ( 6122 ): 966 â 71.
dc.identifier.citedreferenceHeffron R, Celum C, Mugo N, Katabira E, Bukusi E, Tumwesigye E, et al. High initiation of PrEP and ART in a demonstration project among African HIVâ discordant couples. Conference on Retroviruses and Opportunistic Infections (CROI); 2014 Mar 3â 4; Boston, MA.
dc.identifier.citedreferenceStein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990; 80 ( 4 ): 460 â 2.
dc.identifier.citedreferenceWhitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert JH, et al. Acceptability of Carraguard vaginal microbicide gel among HIVâ infected women in Chiang Rai, Thailand. PLoS One. 2011; 6 ( 9 ): e14831.
dc.identifier.citedreferencePool R, Whitworth JA, Green G, Mbonye AK, Harrison S, Wilkinson J, et al. An acceptability study of femaleâ controlled methods of protection against HIV and STDs in southâ western Uganda. Int J STD & AIDS. 2000; 11 ( 3 ): 162 â 7.
dc.identifier.citedreferenceHoffman S, Morrow KM, Mantell JE, Rosen RK, Carballoâ Dieguez A, Gai F. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial. Arch Sex Behav. 2010; 39 ( 3 ): 748 â 60.
dc.identifier.citedreferenceRosen RK, Morrow KM, Carballoâ Dieguez A, Mantell JE, Hoffman S, Gai F, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixedâ methods study. J Women’s Health. 2008; 17 ( 3 ): 383 â 92.
dc.identifier.citedreferencevan der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012; 16 ( 7 ): 1775 â 86.
dc.identifier.citedreferenceMontgomery ET, Cheng H, van der Straten A, Chidanyika AC, Lince N, Blanchard K, et al. Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav. 2010; 14 ( 3 ): 629 â 38.
dc.identifier.citedreferenceGafos M, Mzimela M, Sukazi S, Pool R, Montgomery C, Elford J. Intravaginal insertion in KwaZuluâ Natal: sexual practices and preferences in the context of microbicide gel use. Cult Health Sex. 2010; 12 ( 8 ): 929 â 42.
dc.identifier.citedreferenceGreen G, Pool R, Harrison S, Hart GJ, Wilkinson J, Nyanzi S, et al. Female control of sexuality: illusion or reality? Use of vaginal products in south west Uganda. Soc Sci Med. 2001; 52 ( 4 ): 585 â 98.
dc.identifier.citedreferenceMontgomery CM, Gafos M, Lees S, Morar NS, Mweemba O, Ssali A, et al. Reâ framing microbicide acceptability: findings from the MDP301 trial. Cult Health Sex. 2010; 12 ( 6 ): 649 â 62.
dc.identifier.citedreferenceSahinâ Hodoglugil NN, van der Straten A, Cheng H, Montgomery ET, Kacanek D, Mtetwa S, et al. Degrees of disclosure: a study of women’s covert use of the diaphragm in an HIV prevention trial in subâ Saharan Africa. Soc Sci Med. 2009; 69 ( 10 ): 1547 â 55.
dc.identifier.citedreferenceWoodsong C. Covert use of topical microbicides: implications for acceptability and use. Int Fam Plan Perspect. 2004; 30 ( 2 ): 94 â 8.
dc.identifier.citedreferenceMontgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women’s acceptability and adherence to femaleâ initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2011; 15 ( 5 ): 959 â 69.
dc.identifier.citedreferenceSalter ML, Go VF, Celentano DD, Dienerâ West M, Nkhoma CM, Kumwenda N, et al. The role of men in women’s acceptance of an intravaginal gel in a randomized clinical trial in Blantyre, Malawi: a qualitative and quantitative analysis. AIDS Care. 2008; 20 ( 7 ): 853 â 62.
dc.identifier.citedreferenceMngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014; 18 ( 5 ): 849 â 54.
dc.identifier.citedreferenceGreene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among highâ risk women in Africa and India. Cult Health Sex. 2010; 12 ( 7 ): 739 â 54.
dc.identifier.citedreferenceMuchomba FM, Gearing RE, Simoni JM, Elâ Bassel N. State of the science of adherence in preâ exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012; 61 ( 4 ): 490 â 8.
dc.identifier.citedreferenceWoodsong C, MacQueen K, Amico KR, Friedland B, Gafos M, Mansoor L, et al. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc. 2013; 16: 18505.
dc.identifier.citedreferenceWoodsong C, Macqueen K, Namey E, Sahay S, Morar N, Mlingo M, et al. Women’s autonomy and informed consent in microbicides clinical trials. J Empir Res Hum Res Ethics. 2006; 1 ( 3 ): 11 â 26.
dc.identifier.citedreferencePistorius AG, van de Wijgert JH, Sebola M, Friedland B, Nagel E, Bokaba C, et al. Microbicide trials for preventing HIV/AIDS in South Africa: phase II trial participantsâ experiences and psychological needs. SAHARA J. 2004; 1 ( 2 ): 78 â 86.
dc.identifier.citedreferenceMarlow HM, Tolley EE, Kohli R, Mehendale S. Sexual communication among married couples in the context of a microbicide clinical trial and acceptability study in Pune, India. Cult Health Sex. 2010; 12 ( 8 ): 899 â 912.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferenceBarker G, Ricardo C, Nascimento M. Engaging men and boys in changing genderâ based inequity in health: evidence from programme interventions. Geneva: World Health Organization; 2007.
dc.identifier.citedreferenceShattuck D, Kerner B, Gilles K, Hartmann M, Ng’ombe T, Guest G. Encouraging contraceptive uptake by motivating men to communicate about family planning: the Malawi Male Motivator project. Am J Public Health. 2011; 101 ( 6 ): 1089 â 95.
dc.identifier.citedreferenceBecker S. Couples and reproductive health: a review of couple studies. Stud Fam Plan. 1996; 27 ( 6 ): 291 â 306.
dc.identifier.citedreferenceWorld Health Organization. Male involvement in the prevention of motherâ toâ child transmission of HIV. Geneva: World Health Organization; 2012.
dc.identifier.citedreferenceAluisio A, Richardson BA, Bosire R, Johnâ Stewart G, Mboriâ Ngacha D, Farquhar C. Male antenatal attendance and HIV testing are associated with decreased infant HIV infection and increased HIVâ free survival. J Acquir Immune Defic Syndr. 2011; 56 ( 1 ): 76 â 82.
dc.identifier.citedreferenceMcCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIVâ 1 infection (Microbicides Development Programme 301): a phase 3, randomised, doubleâ blind, parallelâ group trial. Lancet. 2010; 376 ( 9749 ): 1329 â 37.
dc.identifier.citedreferenceMontgomery CM, Pool R. Critically engaging: integrating the social and the biomedical in international microbicides research. J Int AIDS Soc. 2011; 14 (Suppl 2 ): S4.
dc.identifier.citedreferenceMontgomery CM, Watts C, Pool R. HIV and dyadic intervention: an interdependence and communal coping analysis. PLoS One. 2012; 7 ( 7 ): e40661.
dc.identifier.citedreferencePool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One. 2010; 5 ( 7 ): e11600.
dc.identifier.citedreferenceSkolerâ Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, doubleâ blind, placeboâ controlled trial. Lancet. 2008;372 (9654): 1977 â 87.
dc.identifier.citedreferenceAbbott S, Friedland B, Katzen L. Health concerns and HIV risk perception as motives to join a clinical trial. 36th Annual Psychosocial Workshop; 2007 Apr 15â 16; New Orleans, Louisiana.
dc.identifier.citedreferenceAbbott S, Friedland B, Katzen L, de Kock A, Madiba S, Cishe S. Decision making and the influences of others in the informed consent process: a qualitative investigation in the Phase 3 study of Carraguard®. International Microbicides Conference; 2008 Feb 24â 27; New Dehli, India.
dc.identifier.citedreferenceAbbott S, Friedland B, Katzen L, Madiba S, de Kock A, Cishe S. What motivates women to enroll in microbicide clinical trials: results from the Phase 3 Carraguard® Trial. XVII Annual International AIDS Conference; 2010 Aug 3â 8; Mexico City, Mexico.
dc.identifier.citedreferenceKatzen L, Friedland B, Abbott S, de Kock A, Madiba S, Cishe S. Qualitative evaluation of the informed consent process in the Phase 3 Carraguard® Efficacy Trial: study staff experiences and recommendations for future trials. International Microbicides Conference; 2008 Feb 24â 27; New Dehli, India.
dc.identifier.citedreferenceMadiba S, Friedland B, Abbott S, Katzen L, de Kock A, Cishe S. Male partner involvement in the Carraguard ® Phase 3 Trial: data from a qualitative study of the informed consent process. International Microbicides Conference; 2008 Feb 24â 27; New Dehli, India.
dc.identifier.citedreferenceAbbott S, Morar N, Madiba S, Katzen L, Phillip J, Mokgatleâ Nthabu M, et al. Microbicides acceptability: the influence of social and cultural norms, interpersonal relations and sexual socialization. International Microbicides Conference; 2010 May 23; Pittsburgh, PA.
dc.identifier.citedreferencede Kock A, Abbott S, Morar N, Friedland B, Mtimkulu V, Cishe S, et al. Exploring microbicide acceptability in terms of socioâ cultural norms, relationships and product attributes in the Carraguard ® Phase 3 Trial in South Africa. XVII Annual International AIDS Conference; 2008 Aug 3â 8; Mexico City, Mexico.
dc.identifier.citedreferenceMarrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3â 6; Atlanta, GA.
dc.identifier.citedreferencevan der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal preâ exposure prophylaxis: the VOICEâ C qualitative study in Johannesburg, South Africa. PLoS One. 2014; 9 ( 2 ): e89118.
dc.identifier.citedreferenceCohen CR, Brown J, Moscicki AB, Bukusi EA, Paull JR, Price CF, et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel(R)) in healthy young women administered twice daily for 14 days. PLoS One. 2011; 6 ( 1 ): e16258.
dc.identifier.citedreferenceHeadley J, Baumgartner JN, Kaaya S, Minja A, Kalungula H, Bangapi D, et al. Adolescent and young women’s acceptability and use of a proxy microbicide gel or pill in a mock trial in Tanzania. 4th International Workshop on HIV & Women; 2014 Jan 13â 14; Washington, DC.
dc.identifier.citedreferenceTolley E, Kaaya S, Kaale A, Kalungula H, Headley J, Baumgartner JN. Do adolescents under 18 years old warrant inclusion in HIV prevention clinical research? Comparing sexual risk patterns of adolescent and young adult women in a mock trial in Tanzania. XIX International AIDS Conference; 2012 Jul 22â 27; Washington, DC.
dc.identifier.citedreferenceBaumgartner JN, Kaaya S, Kaale A, Headley J, Tolley E. Domestic violence among adolescents and young women in HIV prevention research in Tanzania: participant experiences and measurement issues. XIX International AIDS Conference; 2012 Jul 22â 27; Washington, DC.
dc.identifier.citedreferenceTolley E, Kaaya S, Bangapi D, Minja A, Headley J, Kaale A, et al. Feasibility of recruiting adolescent women into a mock HIV prevention trial. XIX International AIDS Conference; 2012 Jul 22â 27; Washington, DC.
dc.identifier.citedreferenceTolley E, Baumgartner JN, Kaaya S, Sastry J, Headley J. Adolescent sexual risk and perceived need for PrEP: paving the way for their future participation in HIV prevention trials. International Microbicides Conference; 2012 Apr 15â 18; Sydney, Australia.
dc.identifier.citedreferenceBaumgartner JN, Tolley E, Kaaya S, Sastry J, Headley J. Adolescent and community perspectives on microbicide trial participation in Tanzania and India. International Microbicides Conference; 2012 Apr 15â 18; Sydney, Australia.
dc.identifier.citedreferenceSastry J, Tolley E. Research on adolescent sex: to do or not to do. International Microbicides Conference; 2012 Apr 15â 18; Sydney, Australia.
dc.identifier.citedreferenceVenables E, Stadler J. â The study has taught me to be supportive of herâ : empowering women and involving men in microbicide research. Cult Health Sex. 2012; 14 ( 2 ): 181 â 94.
dc.identifier.citedreferencePadian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007; 370 ( 9583 ): 251 â 61.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 â 74.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 ( 27 ): 2587 â 99.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367 ( 5 ): 423 â 34.
dc.identifier.citedreferenceChoopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, doubleâ blind, placeboâ controlled phase 3 trial. Lancet. 2013; 381 ( 9883 ): 2083 â 90.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 ( 5 ): 399 â 410.
dc.identifier.citedreferencevan der Straten A, van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of preâ exposure prophylaxis trials for HIV prevention. AIDS. 2012; 26 ( 7 ): F13 â 9.
dc.identifier.citedreferencevan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367 ( 5 ): 411 â 22.
dc.identifier.citedreferenceInternational Partnership for Microbicides. Two phase III sister studies of a microbicide ring to prevent HIV: the Ring Study & ASPIRE. International Partnership for Microbicides [cited 2014 Jun 28]; Available from: http://www.ipmglobal.org/node/668.
dc.identifier.citedreferenceMacqueen KM, Alleman P. International perspectives on the collection, storage, and testing of human biospecimens in HIV research. Ethics Hum Res. 2008; 30 ( 4 ): 9 â 14.
dc.identifier.citedreferencevan der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal preâ exposure prophylaxis: the VOICEâ C qualitative study in Johannesburg, South Africa. PLoS One. 2014; 9 ( 2 ): e89118.
dc.identifier.citedreferenceMack N, Robinson ET, MacQueen KM, Moffett J, Johnson LM. The exploitation of â Exploitationâ in the tenofovir prep trial in Cameroon: lessons learned from media coverage of an HIV prevention trial. J Empir Res Hum Res Ethics. 2010; 5 ( 2 ): 3 â 19.
dc.identifier.citedreferenceSaethre E, Stadler J. Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa. Med Anthropol Q. 2013; 27 ( 1 ): 103 â 20.
dc.identifier.citedreferenceWoodsong C, Macqueen K, Namey E, Sahay S, Morar N, Mlingo M, et al. Women’s autonomy and informed consent in microbicides clinical trials. J Empir Res Hum Res Ethics. 2006; 1 ( 3 ): 11 â 26.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jia29419.pdf
Size:
4.288MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.